Abstract
Human African and American trypanosomiasis are the vector-borne parasitic diseases that have killed millions of people early, and many people are yet suffering from these neglected diseases. The causative agents of these infections are parasitic protozoans of the genus Trypanosoma. Current treatment regimens against these endemic diseases have several limitations in terms of safety, efficacy, route of administration, and some of them have lost efficacy due to the emergence of resistance in their respective parasites. In this review, the most promising compounds identified by different strategies of drug development against these neglected diseases including target-based approach, the phenotypic high-throughput screening, the drug repurposing approach and combination therapy are emphasized. The potent heterocyclic compounds currently undergoing pre-clinical or clinical studies have also been assessed to ascertain an effective class of organic compounds having significant therapeutic potential against these tropical diseases. The molecular hybridization of outlined motifs may result in more active compounds and circumvent the development of resistance by specific targets in future.
Keywords: Human African trypanosomiasis, chagas disease, pathogens, treatment regimens, drug development, Trypanosoma cruzi.
Current Medicinal Chemistry
Title:Advances in Drug Discovery against Neglected Tropical Diseases: Human African and American Trypanosomiasis
Volume: 28 Issue: 36
Author(s): Mudasir Nabi Peerzada, Aysha Gaur and Amir Azam*
Affiliation:
- Medicinal Chemistry Research Laboratory, Department of Chemistry, Jamia Millia Islamia, Jamia Nagar, New Delhi-110025,India
Keywords: Human African trypanosomiasis, chagas disease, pathogens, treatment regimens, drug development, Trypanosoma cruzi.
Abstract: Human African and American trypanosomiasis are the vector-borne parasitic diseases that have killed millions of people early, and many people are yet suffering from these neglected diseases. The causative agents of these infections are parasitic protozoans of the genus Trypanosoma. Current treatment regimens against these endemic diseases have several limitations in terms of safety, efficacy, route of administration, and some of them have lost efficacy due to the emergence of resistance in their respective parasites. In this review, the most promising compounds identified by different strategies of drug development against these neglected diseases including target-based approach, the phenotypic high-throughput screening, the drug repurposing approach and combination therapy are emphasized. The potent heterocyclic compounds currently undergoing pre-clinical or clinical studies have also been assessed to ascertain an effective class of organic compounds having significant therapeutic potential against these tropical diseases. The molecular hybridization of outlined motifs may result in more active compounds and circumvent the development of resistance by specific targets in future.
Export Options
About this article
Cite this article as:
Peerzada Nabi Mudasir , Gaur Aysha and Azam Amir *, Advances in Drug Discovery against Neglected Tropical Diseases: Human African and American Trypanosomiasis, Current Medicinal Chemistry 2021; 28 (36) . https://dx.doi.org/10.2174/0929867328666210504111442
DOI https://dx.doi.org/10.2174/0929867328666210504111442 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biosimilars: Current Scientific and Regulatory Considerations
Current Clinical Pharmacology Medical Expert Systems
Current Bioinformatics Sealing the Broken Barrier in IBD: Intestinal Permeability, Epithelial Cells and Junctions
Current Drug Targets Matrix Metalloproteinases in Vascular Disease - A Potential Therapeutic Target?
Current Vascular Pharmacology Epidemiology and Costs of Hypertension-related Disorders
Current Pharmaceutical Design Effect of L-Arginine and Selenium on Metabolic Features, Insulin Resistance and Hepatic Function Tests in Obese Women
Current Nutrition & Food Science Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis
Current Topics in Medicinal Chemistry Serum Procalcitonin Levels in Febrile Patients with Systemic Autoimmune Diseases
Current Rheumatology Reviews Molecular Aspects of Adipokine-Bone Interactions
Current Molecular Medicine Dietary Intake and Physical Activity in a Canadian Population Sample of Male Patients with HIV Infection and Metabolic Abnormalities
Current HIV Research The Role of Microbiota and Probiotics in Stress-Induced Gastrointestinal Damage
Current Molecular Medicine IL-15 and HIV Infection: Lessons for Immunotherapy and Vaccination
Current HIV Research Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A Relationship with Implications for Vascular Risk?
Current Vascular Pharmacology Arsenic Immunotoxicity and Immunomodulation by Phytochemicals: Potential Relations to Develop Chemopreventive Approaches
Recent Patents on Inflammation & Allergy Drug Discovery Bioinformatics Approach to BDNF and BDNF-Related Disorders
Current Neuropharmacology Chemical and Genetic Engineering Strategies to Improve the Potency of Pharmaceutical Proteins and Enzymes
Current Medicinal Chemistry The Therapeutic Role of Renin-Angiotensin System Blockers in Obesity- Related Renal Disorders
Current Clinical Pharmacology Epigenetics, Depression and Antidepressant Treatment
Current Pharmaceutical Design Alpha-7 Nicotinic Receptors in Nervous System Disorders: From Function to Therapeutic Perspectives
Central Nervous System Agents in Medicinal Chemistry Potential Disease Targets for Drugs that Disrupt Protein - Protein Interactions of Grb2 and Crk Family Adaptors
Current Pharmaceutical Design